Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Equity Capital Markets

Shandong BoAn Biotechnology  / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shandong-boan-biotechnology-co" target="_blank" data-smartkarma-citation="entities:35966:1" rel="noopener">Shandong BoAn Biotechnology (6955 HK)</a> is placing 48M shares, representing 7.7% of the total number of issued shares post placement. Placement price is HK$16.42, 9% discount to last undisturbed price.  </li>
<li>The expected net proceeds of ~HK$780M will be used for funding R&amp;D of innovative product candidates and commercialization of marketed and upcoming products.</li>
<li>This is the second placement of the company this year. In June, Boan Biotech raised ~HK$396M through placing 26.7M shares. The company is not expected to raise fund anytime soon.</li>
</ul>



Shandong BoAn Biotechnology (6955 HK) is placing 48M shares, representing 7.7% of the total number of issued shares post placement. Placement price is HK$16.42, 9% discount to last undisturbed price.  
The expected net proceeds of ~HK$780M will be used for funding R&amp;D of innovative product candidates and commercialization of marketed and upcoming products.
This is the second placement of the company this year. In June, Boan Biotech raised ~HK$396M through placing 26.7M shares. The company is not expected to raise fund anytime soon.


BoAn Biotechnology (6955 HK): Profitable Operation & Pipeline Progress Make the Placement Attractive